The portfolio maintains a sizable cost advantage over competitors, priced within the lowest fee quintile among peers.
Franklin Genomic Advancements ETF HELX
Morningstar’s Analysis HELX
Will HELX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 46.6
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Medpace Holdings Inc | 5.70 | 551,516 | Healthcare |
Vertex Pharmaceuticals Inc | 5.36 | 518,888 | Healthcare |
Danaher Corp | 5.32 | 514,797 | Healthcare |
Regeneron Pharmaceuticals Inc | 5.21 | 504,662 | Healthcare |
Thermo Fisher Scientific Inc | 5.06 | 490,307 | Healthcare |
Eli Lilly and Co | 4.74 | 459,084 | Healthcare |
Krystal Biotech Inc | 4.25 | 410,965 | Healthcare |
Natera Inc | 3.89 | 376,657 | Healthcare |
Samsung BioLogics Co Ltd | 3.78 | 365,767 | Healthcare |
AstraZeneca PLC ADR | 2.66 | 257,233 | Healthcare |